AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01273753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic exercise
Description: Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
Study NCT04208607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Role of bronchoscopy in diagnosis of bronchiectasis
Study NCT01449799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram dose
Description: To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
Study NCT01449799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 500 microgram dose
Description: To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
Study NCT01449799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Description: To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
Study NCT01449799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend
Description: To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
Study NCT01763840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast enhanced Ultrasound
Description: Ultrasound, then contrast enhanced ultrasound.
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenously daily on days -5, -4, -3.
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: 1.0 mg/kg intravenously over 4 hours (day -2 and -1).
Study NCT00899431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplantation
Description: On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
Study NCT00899431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
Study NCT04509661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LABA/LAMA or Placebo inhalation
Description: Inhaled LABA/LAMA for one year.
Study NCT04509661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/LAMA or Placebo inhalation
Description: Inhaled LABA/LAMA for one year.
Study NCT02860429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinobufacini injection
Description: cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
Study NCT02860429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
Study NCT02860429 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: chemotherapy
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
Study NCT00006289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.
Study NCT00006289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.
Study NCT02098668 — intervention group
Intervention type: OTHER
Intervention: Fertility treatment
Description: Fertility treatment
Study NCT02465099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Dissection (UD)
Description: Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
Study NCT02465099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery Dissection (ED)
Description: Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
Study NCT01966848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wich prosthesis is used
Study NCT02605460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
Study NCT02605460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
Study NCT02605460 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CXCR4 Antagonist
Description: 24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
Study NCT02605460 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic Stem Cell Transplantation
Description: Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
Study NCT00703248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatments
Description: 1. opening the thoracic inlet~2. pectoral traction for 1 minute bilaterally~3. rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine \]~4. thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~5. abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally.
Study NCT00773604 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic implantable deep brain stimulation (DBS) system
Description: surgical placement of deep brain stimulation system for treatment of dystonia
Study NCT03727724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Tablet
Study NCT03727724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Injection
Study NCT04282330 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D CEST imaging
Description: Chemical Exchange Saturation Transfer (CEST) is an emerging MRI technique that can acquire multiple endogenous contrasts to probe cerebral metabolism.
Study NCT03159793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Modelling Technique
Description: Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
Study NCT03159793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Filmed Modelling technique
Description: Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
Study NCT03520504 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton craniospinal irradiation (CSI)
Description: Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
Study NCT04112381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Model 4000 Type 1.0/1.1
Description: Exablate thalamotomy of non tremor dominant side of the brain
Study NCT03339752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg tablet
Study NCT03339752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: 10 mg tablet
Study NCT03339752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: 25 mg hard capsule
Study NCT03339752 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ACT-541468
Description: 25 mg hard capsule
Study NCT03462693 — intervention group
Intervention type: OTHER
Intervention: Dry needling
Description: The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
Study NCT01148979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (Vyvanse)
Description: Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
Study NCT01148979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
Study NCT00056069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
Study NCT01646125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
Study NCT01646125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
Study NCT01646125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
Study NCT01516541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background care
Description: Guidelines-based medical care
Study NCT01516541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Background care
Description: Guidelines-based medical care
Study NCT01516541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching dalcetrapib placebo orally daily
Study NCT01516541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 600 mg orally daily
Study NCT02978781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Oral Solution
Study NCT02978781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 Capsules
Study NCT02978781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo capsules
Study NCT01757925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight managment program
Description: a comprehensive peditric weight management program consisting of 16 weekly group sessions
Study NCT01757925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight managment program
Description: a comprehensive peditric weight management program consisting of 16 weekly group sessions
Study NCT01757925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Gaming
Description: partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
Study NCT04678219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects will be placed on 1 of 2 diets for a treatment period of 8 weeks with the support of dietitians; it will then be evaluated whether they can continue this diet on their own for 4 weeks.
Study NCT01549418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (ASA)
Description: Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
Study NCT01549418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Adhesive Bandage #1
Description: On the randomized wound site, a marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Bandage #2
Description: On the randomized wound site, a marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Marketed Bandage #1
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Bandage #2
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #3
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #4
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.
Study NCT04040933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Marketed Adhesive Bandage #5
Description: On the randomized wound site, a non-marketed adhesive bandage will be applied.
Study NCT02029248 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Study NCT06022692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
Description: The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
Study NCT06022692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab (BeiGene, China) combined with PD-1 inhibitor
Description: The patients were treated with whole-body hyperthermia (HECKEL 3000MT-4T, Germany)) on days 1 and 8 of each hyperthermia combined with immune checkpoint inhibitor treatment cycle along with administration of tislelizumab (BeiGene, China) 200 mg on day 2 (24 hours after the hyperthermia at day 1).
Study NCT03515668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin 20 mg Tablet
Description: Single dose for all participants
Study NCT03515668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo with same appearance/taste
Study NCT02455830 — intervention group
Intervention type: BIOLOGICAL
Intervention: Autologous cord blood cell therapy
Description: The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
Study NCT00598000 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits.
Study NCT02409277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Standard vs Intensive e-AT Intervention
Description: Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
Study NCT03024099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy once a week
Description: Hippotherapy once a week
Study NCT03024099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy twice a week
Description: Hippotherapy twice a week
Study NCT03307876 — intervention group
Intervention type: OTHER
Intervention: autologous PPP injection
Description: autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT01284335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636
Description: Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
Study NCT04675008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis
Study NCT03016000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
Study NCT03016000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Just observation
Study NCT03620877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized intervention
Description: Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
Study NCT04333719 — intervention group
Intervention type: OTHER
Intervention: Type of sedations
Description: Estimate the prevalence of deep sedations (i.e. with a -4 or -5 score at the Richmond scale at the induction time) for patients in terminal phase and receiving cares from a specialized palliative care facility
Study NCT02830685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTI with Acellular Dermal Matrix (CELLIS® Breast)
Description: After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.